BioSpace News Archive

Precigen ActoBio, an innovative clinical-stage biotechnology company focused on a new class of microbe-based therapeutic agents and a wholly-owned subsidiary of Precigen, Inc. (Nasdaq: PGEN), today announced positive topline results for the ongoing Phase 1b/2a clinical study investigating AG019 ActoBiotics™ for the treatment of recent-onset type 1 diabetes (T1D)

Nyxoah SA (Euronext Brussels: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company has publicly filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission

Nyxoah SA, a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea, announced its unaudited, interim financial statements for the three months ended March 31, 2021.

Today, Bristol Myers Squibb (NYSE: BMY) and GRYT Health unveiled the “Advocacy Exchange,” an evolution of the existing COVID Advocacy Exchange, an enduring community built to support patient advocacy organizations by providing access to educational resources, encouraging ongoing dialogue, and sharing best practices among participants.

Increasing significance of contract research organizations in drug discovery initiatives is driving revenue growth of the market.

The signaling molecule hydrogen sulfide (H2S) plays a critical role in antibiotic tolerance, the innate ability of bacteria to survive normally lethal levels of antibiotics, a new study finds.

Clovis Oncology, Inc. announced partial results and the partial adjournment of its 2021 Annual Meeting of Stockholders.

Mirum Pharmaceuticals, Inc. announced that on May 10, 2021, the Compensation Committee of Mirum’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 191,400 shares of common stock to 17 new employees under Mirum’s 2020 Inducement Plan.

Increasing importance of stem cells in regenerative medicine and tissue engineering, growing network of stem cell banks, and rising awareness regarding benefits of stem cell preservation are key factors driving market growth.

Shift in diagnostics from centralized labs toward practitioners’ offices to drive market growth.